Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma

Similar documents
Thai Journal of Pharmaceutical Sciences (TJPS)

Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064nm) laser for the treatment of facial melasma in local population

A STUDY OF EFFICACY RESULT BETWEEN TOPICAL HERBAL RHUBARB LIQUID AND LIQUID BASE FOR THE TREATMENT OF MELASMA IN THAI PEOPLE

SPECIAL TOPIC. Institut National de la Sante et de la Recherche Medicale (INSERM U895), Nice, France c

JMSCR Vol 06 Issue 02 Page February 2018

JUST SEE ME! PIGMENTATION SOLUTIONS FOR HIGHER FITZPATRICKS

The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial

Efficacy and safety of 2% kojic acid containing formulation versus modified Kligman s formula in melasma - a comparative study

Department of Dermatology, Nishtar Medical College/Hospital, Multan

BRAND SPECIALISING IN THE TREATMENT OF DARK SPOTS

Melasma is one of the most common and

A double-blind controlled study of a nonhydroquinone bleaching cream in the treatment of melasma

An Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma

Treatment Seeking Behavior In Patients Suffering From Melasma Aneela Asghar, Tariq Rashid

JMSCR Vol 06 Issue 05 Page May 2018

MELASMA Photoprotection and light devices

Pathophysiology of melasma. Emel ERDAL ÇALIKOĞLU

Melasma is acquired and

Comparative study of therapeutic efficacy of intralesional vitamin D3 versus intralesional purified protein derivative in the treatment of warts

A double-blind controlled study of a nonhydroquinone bleaching cream in the treatment of melasma

This PDF is available for free download from a site hosted by Medknow Publications

Therapeutic Effect of Topical Application of Linoleic Acid and Lincomycin in Combination with Betamethasone Valerate in Melasma Patients

An In-Depth Look at the Function and Efficacy of Oral Glutathione for Skin Care

Vitiligo is a skin depigmentation disorder

ALPHA-ARBUTIN Superior skin lightening enhancer for a perfect even skin tone

Dermatophytosis: a clinical study and efficacy of KOH examination as compared to culture

Prospective Study of Response to NBUVB in Various Forms of Vitiligo in Different Age Groups.

Trichloroacetic Acid Peel 15% + NB-UVB Versus Trichloroacetic Acid Peel 25% + NB-UVB for Stable Non-Segmental Vitiligo

Peeling. Smooth out the skin. Remove the outer skin layers. Erase the fine wrinkles. The regenerated skin is smoother & Less wrinkled - Renewed

A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients

Treatment Evaluation of Melasma Patients in Dr. Hasan Sadikin General Hospital Bandung in period of

Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm)

Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada

EFFICACY OF TRANEXAMIC ACID INTRADERMAL MICROINJECTIONS REDUCING RISK OF POSTINFLAMMATORY HYPERPIGMENTATION AFTER Q-SWITCHED ND: YAG LASER FOR THE

Menegament of Melasma with Ablative Laser Treatment ŞERAFETTİN SARAÇOĞLU, MD DERMATOLOGIST

Partial Unilateral Lentiginosis Treated with 532-nm and Subsequent Low-Fluence 1,064-nm Q-Switched Neodymium-Doped Yttrium Aluminum Garnet Lasers

The Efficacy and Safety of Bipolar Radiofrequency Treatment with Non-Insulated Penetrating Microneedles for Acne Vulgaris and Acne Scars

COSMELAN DEPIGMENTATION TREATMENT

Relation between the Peripherofacial Psoriasis and Scalp Psoriasis

Tranexamic Acid Diminishes Laser-Induced Melanogenesis

Therapeutic Efficacy and Safety of Invasive Pulsed-Type Bipolar Alternating Current Radiofrequency on Melasma and Rebound Hyperpigmentation

A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy according to the Density of Ablative Laser Channel

Short-term Effects of 308-nm Xenon-chloride Excimer Laser and Narrow-band Ultraviolet B in the Treatment of Vitiligo: A Comparative Study

HYDRACARE LIGHTENING BUSINESS OPPORTUNITY

Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split-face trial

LUMACIP PLUS Cream (Fluocinolone acetonide 0.01% + Hydroquinone 4% + Tretinoin 0.05%)

ACTIVE.LITE. Patent-Pending Technology + Visibly Perceivable Results in Less than 14 Days. Tomorrow s Vision Today!

Effect of tranexamic acid on melasma: a clinical trial with histological evaluation

ISPUB.COM. A Case of Actinic Lichen Planus. K Choi, H Kim, H Kim, Y Park INTRODUCTION CASE REPORT

Vitiligo. Vasanop Vachiramon, MD. Assistant professor Division of Dermatology, Ramathibodi Hospital

Solar Lentigines: Evaluating Pulsed Dye Laser (PDL) as an Effective Treatment Option

combining Fractional RF and Superficial RF

1,927-nm Fractional Thulium Fiber Laser for the Treatment of Nonfacial Photodamage: A Pilot Study

A Clinical Trial of Topical Bleaching Treatment with Nanoscale Tretinoin Particles and Hydroquinone for Hyperpigmented Skin Lesions

Epidemiological study, clinical spectrum and associations of childhood vitiligo in a tertiary care centre

Azelaic Acid is an Effective and Safer Alternative to Hydroquinone in Treating Mild to Moderate Melasma in Women

NO MORE NEWS AN EVIDENCE BASED APPROACH ON LASERS IN SKIN OF COLOR PATIENTS DR. EDUARDO WEISS, M.D., FAAD

Asian skin rejuvenation with PicoFractional laser

CRÈME PIGM 400 TREATMENT STAGE

Experience with a Strong Bleaching Treatment for Skin Hyperpigmentation in Orientals

Treatment of Melasma Using a Novel 1,927 nm Fractional Thulium Laser: A Retrospective Analysis of 68 Korean Patients

Bangladesh Journal of Medical Science Vol. 11 No. 03 July 12. Original Article

Melasma: Treatment Approaches

Sun Safety and Skin Cancer Prevention. Maryland Skin Cancer Prevention Program

Deoxyarbutin. Product Data sheet DEFINITIONDEFINITIO DEFINITION

BV OSC BARNET. A Quasi Drug Whitening Benchmark. Superior Skin Penetration Compared to Other Whiteners Reduces Age Spots Great Stability in Formulas

Clinical Study A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma

Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial

Clinical Study Narrow-Band Ultraviolet B versus Oral Minocycline in Treatment of Unstable Vitiligo: A Prospective Comparative Trial

Hyperpigmentation my approach. Dr. Peter Velthuis Dermatologist Erasmus Medical Centre, Rotterdam

Efficacy and safety of ablative fractional carbon dioxide laser for acne scars

The efficacy of the treatment of abdominal cellulite and skin tightening with a Venus Freeze (MP) 2 -A pilot study.

The A To Z Of Skincare Ingredients

Casnigo, April, the 21 st, Operative Protocols for PRISMA Nd: YAG laser 1440

Malignant Melanoma Early Stage. A guide for patients

Luisant Mela X Free from AGEs-Induced Epidermal Pigmentation

Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids

Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: A prospective study

SPECIAL TOPIC. AboutSkin Dermatology & DermSurgery, Greenwood Village, CO b. The Aesthetic Clinique, Destin, FL c

SKIN WHITENING. XII November 2017 N 8. Maurizio Ceccarelli & Coll. Protocol for skin pigmentation treatment.

Therapeutic Efficacy and Safety of Wavelength-Converted 660-nm Q-Switched Ruby-Like Versatile YAG Treatment on Various Skin Pigmentation Disorders

Clinical Course of Segmental Vitiligo: A Retrospective Study of Eighty-Seven Patients

Original Policy Date

OA(Original Article) Key words Asian; Melasma; Fractional photothermolysis; Topical drugs

Vitiligo is an acquired cutaneous disorder of


Microneedling for acne scars in Asian skin type: an effective low cost treatment modality

นพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด

Lichenoid Tissue Reaction in Malignant Melanoma A Potential Diagnostic Pitfall

For skin care professionals. Only Obagi

When hyperpigmentation brings patients to your office, be prepared to offer effective, efficient interventions. By Rebat M. Halder, MD Washington, DC

Successful Treatment of Refractory Melasma Using Invasive Micro-Pulsed Electric Signal Device

Update on Melasma. Melasma Affects QOL. Acquired Disorders of Hyperpigmentation. Melasma is Often a Chronic Disorder

A Vitiligo Update for Pharmacists: Current Practices and Future Advances

Unmasking Facial Hyperpigmentation

Research Article An Open Randomized Comparative Study of Various Intralesional Immunotherapeutic Agents in Cutaneous Warts

Clinical Benefit of Combination Treatment with 1,550 nm Fractional Laser and a New Wavelength at 1,927 nm on Photorejuvenation in Asian Patients

Abrupt Intralesional Color Change on Dermoscopy as a New Indicator of Early Superficial Spreading Melanoma in a Japanese Woman

A New Bleaching Protocol for Hyperpigmented Skin Lesions with a High Concentration of All-trans Retinoic Acid Aqueous Gel

Transcription:

International Journal of Research in Dermatology http://www.ijord.com Original Research rticle DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20183159 Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma Vinma H. Shetty*, Monisha Shetty Department of Dermatology, Venereology, Leprosy, J Institute of Medical Sciences, Mangalore, Karnataka, India Received: 02 pril 2018 Revised: 08 May 2018 ccepted: 09 May 2018 *Correspondence: Dr. Vinma H. Shetty, E-mail: vinma_shetty@yahoo.co.in Copyright: the author(s), publisher and licensee Medip cademy. This is an open-access article distributed under the terms of the Creative Commons ttribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. BSTRCT Background: Melasma is an acquired hypermelanosis affecting the sun- exposed areas of the skin, most commonly the face and neck. Different treatment modalities have been utilized in different studies with varying, not so satisfactory outcomes. The aim of the study was to compare the efficacy of localized intradermal microinjection of tranexamic acid with oral tranexamic acid in melasma patients. Methods: It is a prospective comparative study. ll patients enrolled in the study were divided into 2 groups - twenty in each treatment group. In group, patients were given intradermal injections of tranexamic acid (4 mg/ml) once at three week intervals (0, 3, 6, 9, 12 weeks) for 12 weeks. patients were given oral tranexamic acid 250 mg twice a day for 12 weeks. Following parameters were evaluated before and after 12 weeks of treatment: a) digital photographs b) MSI score c) patient subjective assessment d) dermoscopic photographs. Software (SPSS, version 16.0 statistical packages) was used. Results: Clinical efficacy of the treatment in 2 different groups showed higher efficacy with intradermal microinjection (35.6%) compare to oral tranexamic acid (21.7%). Patient's subjective assessment showed good improvement in 63.15% of cases in group, whereas in group B 27.8% of cases showed good improvement. Conclusions: Intralesional localized microinjection of tranexamic acid is a promising new therapeutic modality for the treatment of resistant melasma. Keywords: Melasma, Tranexamic acid, Microinjection INTRODUCTION Melasma is an acquired, symmetrical hypermelanosis of the face and is particularly seen in women with skin types IV to VI living in areas with intense UV radiation. The exact etiopathogenesis is unknown. However, various etiological factors proposed in the literatureinclude sun exposure, pregnancy, hormonal therapy, genetic factors and vascular factors. 1 Various treatment modalities such as topical depigmenting agents, chemical peels, dermabrasion and laser therapies have been utilised with varying, not so satisfactory outcomes. 2-5 Tranexamic acid, (TX) a plasmin inhibitor, is now gaining popularity as a depigmenting agent. TX prevents the binding of plasminogen to the keratinocytes, which ultimately results in less free arachidonic acids and thus inhibits UV- induced plasmin activity in keratinocytes. 6 Oral TX also produces significant decrease in the mmsi in melasma patients. 7 TX administered intradermally is effective for dermal and mixed variants of melasma. TX is a safe and well International Journal of Research in Dermatology July-September 2018 Vol 4 Issue 3 Page 363

tolerated drug at the usual dosage. 8 The contraindications of the drug include acquired defective colour vision, active intravascular clotting conditions and drug hypersensitivity. 7 In the present study; we are comparing the efficacy of localised intradermal microinjection of tranexamic acid with oral tranexamic acid in melasma patients. METHODS This prospective, comparative study was conducted at J Institute of Medical Sciences, Mangalore, Karnataka from October 2017 to March 2018. In this study, sample size was 40, with twenty in each treatment group. dult males and females between 18 and 50 years of age with skin phototypes II to V according to Fitzpatrick's classification and clinical diagnosis of melisma were included in this study. Informed written consent was taken from all the subjects. The study was approved by Ethical Committee of the Institutional Review Board. Exclusion criteria were clotting disorders, use of anticoagulant, history of hypersensitivity to the vehicle or active substance, history of hormonal therapy, pregnant or lactating females and history of any other depigmenting treatment in the past 1 month. Complete history taking and detailed cutaneous examination with regard to melasma was performed in all subjects. Wood's lamp examination was done to determine the type of melasma. modified MSI (melasma area and severity index) scoring system was used to assess the severity of melasma. Following parameters were evaluated before and after 12 weeks of treatment: a) digital photographs examined by an independent investigator (classified as unchanged, presence or absence of improvement), b) MSI score c) patient subjective assessment (rating the improvement as good, bad and no change) d) dermoscopic photographs. ll patients enrolled in the study were divided into 2 groups, twenty in each treatment group. In group. patients were given intradermal injections of tranexamic acid 0.05 ml (4 mg/ml) in each cm of melasma, after application of topical anaesthesia with lidocaine hydrochloride 2%, once at three week intervals (0, 3, 6, 9, 12 weeks) for 12 weeks. patients were given oral tranexamic acid 250 mg twice a day for 12 weeks. Laboratory tests including complete blood count and coagulation tests were performed on all patients to assess the safety parameters. Patients were instructed to apply only sunscreen SPF 30 every 4 hours during the day while on treatment Efficacy of the treatment was calculated using the formula (mmsi score before-mmsi score after)/mmsi score before 100 (Table 3). Clinical efficacy was categorized into excellent response: if more than 75% fall in mmsi score. Very good response: if 50-75% fall in mmsi score. Good response: if 25-50% fall in mmsi score. Poor response: if less than 25% fall in mmsi score (Table 4). Statistical analysis Software (SPSS, version 16.0 statistical package) was used throughout. Mean and standard deviation was used for continuous variables. P value of less than 0.05 was considered significant. RESULTS Out of forty patients, 37 patients completed the study, 19 in group and 18 in group B. There was no significant difference among the two groups regarding the demographic data such as age of patients and duration of disease (Table 1). The most common detected Fitzpatrick skin phototype was type 4. When we correlated the efficacies of treatment with the demographic factors, we found that treatment efficacy was higher in female patients and in patients with Fitzpatrick skin phototypes of II and III. Younger patients showed faster improvement than the older patients. Patient's age (in years) Duration of disease (in years) Table 1: ge and duration of disease. Range (n=19) 21-48 (n=18) 19-49 Mean±SD 34.0±6.40 32.6±5.90 Range 2-8 1-11 Mean±SD 5.32±2.16 6.48±3.19 The most common type of melasma was malar pattern. Under wood's lamp examination, epidermal type was most common (Table 2). In group patients, mmsi score was 11.83±1.72 at the baseline and it reduced to 7.62±1.64 after 12 weeks. In group B, mmsi score reduced from baseline value of 10.61±1.59 to 8.30±1.92 after 12 weeks. Higher clinical efficacy was observed with intradermal microinjection (35.6%) compare to oral tranexamic acid (21.7%) with p value <0.05 (statistically significant) (Table 3). Patient's global assessment showed good improvement in 63.2% of cases in group, whereas in group B 27.8% of cases showed good improvement (Table 4). Regarding the side effects of the treatment In group, there was erythema and wheal at the site of injection in all patients which lasted for 4-6 hours. In group B, no side effects were reported. International Journal of Research in Dermatology July-September 2018 Vol 4 Issue 3 Page 364

Table 2: Type of Melasma among the study group. (no. of patients) (% of patients) (no. of patients) (% of patients) Malar 15 78.9 11 61.1 Types of melasma Centrofacial 4 21.1 7 38.9 Mandibular 0 0 0 0 Epidermal 10 52.6 9 50 Pattern of melasma Dermal 3 15.8 3 16.7 Mixed 6 31.6 6 33.3 Total 19 18 Table 3: mmsi score for group and B, before and after 12 weeks of treatment. mmsi (n=19) (n=18) Before treatment 11.83±1.72 10.61±1.59 fter treatment 7.62±1.64 8.3±1.92 Percentage of improvement (%) 35.6 21.7 P value <0.001 <0.05 B C D E Figure 1: Intradermal tranexamic acid. () Before treatment; (B) after 2nd session; (C) after 3rd session; (D) after 4th session; (E) after 5th session. International Journal of Research in Dermatology July-September 2018 Vol 4 Issue 3 Page 365

Table 4: Shows the response to treatment in study group. Response to treatment (no. of patients) (% of patients) (no. of patients) (% of patients) Good 12 63.2 5 27.8 Poor 5 26.3 10 55.6 No response 2 10.5 3 16.7 Total 19 18 B C D Figure 2: Oral tranexamic acid. () Before treatment, (B) after six weeks; (C) after nine weeks; (D) after twelve weeks. DISCUSSION Tranexamic acid was reported to be useful in the treatment of melasma in 1979 by Nijor in Japan. 9,10 Tranexamic acid blocks the conversion of plasminogen (present in the epidermal basal cells) into plasmin by inhibiting plasminogen activator. 11,12 The dose of oral TX used in melasma is far less than that prescribed for its hemostatic action. In randomized controlled trial study conducted by Karn et al in Nepal, oral TX was administered to melasma patients in a dose of 250 mg twice daily for 3 months. The authors concluded that it provides a rapid and sustained improvement in the treatment of melasma. 7 Li et al studied TX intradermally on guinea pigs and found that at the basal layer of exposed epidermis, the number of melanocytes remained the same, but the melanin content was significantly lowered. This highlights the fact that TX has no effect on the number of melanocytes but affects melanin expression. 13,14 In group, patients were given intradermal injection of tranexamic acid. This mode of drug delivery showed 35.6% of efficacy with good clinical response. Patient's subjective assessment showed good improvement in 63.15% of cases by photographic evaluation. In another study conducted in Korea on melasma patients, TX was directly administered intradermally (4 mg/ml) weekly for a period of 12 weeks. More than 75% patients experienced a statistically significant improvement. 11 In group B, patients were given oral tranexamic acid. fter 12 weeks of treatment, mmsi score showed significant decrease from the baseline with the clinical efficacy of 21.7%. Patient's subjective assessment showed good improvement in 27.8% of cases by photographic evaluation. Nausea and diarrhoea are the most common side effect. 8 Other systemic side effects observed with low dose administration include oligomenorrhea, gastric upset and palpitations. 15 Though it is used in low doses for a short duration as a systemic depigmenting agent, it is always vital to rule out underlying coagulation defects to prevent untoward adverse events. Wu et al observed a differential response of TX on melasma patients having coexisting freckles and senile lentigo. They noted that the treatment International Journal of Research in Dermatology July-September 2018 Vol 4 Issue 3 Page 366

was unresponsive to freckles and senile lentigo, whereas the melasma responded well. 16 CONCLUSION Tranexamic acid is safe and well tolerated drug for the treatment of melasma. Both intradermal and oral modes of administration are effective for melasma. Intralesional localized microinjection of tranexamic acid is a promising new therapeutic modality for the treatment of resistant melasma. Funding: No funding sources Conflict of interest: None declared Ethical approval: The study was approved by the institutional ethics committee REFERENCES 1. Sarkar R, rora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5:426-35. 2. Gupta K, Gover MD, Nouri K, Taylor S. The treatment of melasma: review of clinical trials. J m cad Dermatol. 2006;55:1048-65. 3. Bentley-Phillips B, Bayles M.Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation fr Med J. 1975;49:1391-5. 4. Hurley ME, Guervara IL, Gonzales RM, Pandya G. Efficacy of glycolic acid peels in the treatment of melasma. rch Dermatol. 2002;138:1578-82. 5. Li YH, Chen JZ, Wei HC, Wu Y, Liu M, Xu YY, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34:693-700. 6. ndo H, Matsui MS, Ichihashi M. Quasi- drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci. 2010;11:2566-75. 7. Karn D, Kc S, matya, Razouria E, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10:40-3. 8. Calapai G, Gangemi S, Mannucci C, Miniullo PL, Casciaro M, Calapai F. Systematic review of tranexamic acid adverse reactions. J Pharmacovigil. 2015;3:1-7. 9. Nijor T. Treatment of melasma with tranexamic acid. Clin Res. 1979;13:3129-31. 10. Malathi M, Thappa DM. Systemic skin whitening/lightening agents: What is the evidence? Indian J Dermatol Venereol Leprol. 2013;79:842-6. 11. Lee JH, Park JG, Lim SH, Kim JY, hn KY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in sian patients: Preliminary Clinical Trial Dermatol Surg. 2006;32:626-31. 12. Maeda K, Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte- conditioned medium. J Health Sci. 2007;53(4):389-96. 13. Li D, Shi Y, Li M, Liu J, Feng X. Tranexamic acid can treat ultraviolet radiation - induced pigmentation in guinea pigs. Eur J Dermatol. 2010;20:289-92. 14. Elfar NN, El Maghraby GM. Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: comparative study. J Clin Exp Dermatol Res. 2015;6:1-7. 15. amir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: pilot study. J Pak ssoc Dermatol. 2014;24:198-203. 16. Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. esthetic Plast Surg. 2012;36:964-70. Cite this article as: Shetty VH, Shetty M. Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma. Int J Res Dermatol 2018;4:363-7. International Journal of Research in Dermatology July-September 2018 Vol 4 Issue 3 Page 367